Long lasting drug formulations
AssigneeMedgenics Medical Israel Ltd.
InventorsANDREW PEARLMAN, BARUCH S. STERN
Life of this patent
Estimating the term…
Abstract
The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.
Claims20
A method of treating anemia in a human subject in need over a sustained time period comprising the steps of:
- a. providing at least one genetically modified micro-organ that expresses and secretes erythropoietin, said micro-organ comprising a helper-dependent adenovirus vector comprising a nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid encoding erythropoietin operably linked to one or more regulatory sequences comprises SEQ ID No. 11;
- b. determining erythropoietin secretion levels of said at least one genetically modified micro-organ in vitro;
- c. implanting said at least one genetically modified micro-organ in said human subject at an effective dosage;
- and
- d. measuring hemoglobin levels in the blood of said subject;
- wherein the measured hemoglobin levels in said subject are maintained at 9-11 g/dl in at least 50% of the measurements for at least one month.
A method of increasing or maintaining physiological hemoglobin levels in a human subject over a sustained period of time comprising the steps of:
- a. providing at least one genetically modified micro-organ that expresses and secretes erythropoietin, said micro-organ comprising a helper-dependent adenovirus vector comprising a nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid encoding erythropoietin operably linked to one or more regulatory sequences comprises SEQ ID No. 11;
- b. determining erythropoietin secretion levels of said at least one genetically modified micro-organ in vitro;
- c. implanting said at least one genetically modified micro-organ in said subject at an effective dosage;
- and
- d. measuring hemoglobin levels in the blood of said subject,
- wherein said increased or maintained physiological hemoglobin levels in said subject are maintained at 9-11 g/dl in at least 50% of the measurements for at least one month.
Dependencies are inferred from the claim text.